Last reviewed · How we verify
Licensed Influenza Vaccine 2
Licensed Influenza Vaccine 2 is a Vaccine Biologic drug developed by BioNTech. It is currently FDA-approved for Influenza prevention, Influenza protection, Influenza prevention for adults and children 6 years and older.
Licensed Influenza Vaccine 2 from BioNTech SE is a marketed vaccine for influenza prevention and protection in adults and children 6 years and older. It has generated significant revenue of $3.42 billion. The vaccine has undergone 83 trials and has 5 publications. Its mechanism is not specified on Wikipedia. The vaccine's clinical differentiation and commercial significance are not well-documented. BioNTech SE is a well-established company in the pharmaceutical industry.
At a glance
| Generic name | Licensed Influenza Vaccine 2 |
|---|---|
| Sponsor | BioNTech |
| Drug class | Vaccine |
| Target | Not specified |
| Modality | Biologic |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
- Influenza prevention
- Influenza protection
- Influenza prevention for adults and children 6 years and older
Common side effects
Drug interactions
- Live vaccines
- Interferons
- Immunosuppressive drugs
- Corticosteroids
- Antiviral drugs
- Corticosteroids
- Immunoglobulins
- Blood products
Key clinical trials
- A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults (PHASE1)
- A Study to Learn About mRNA Vaccines Against Influenza in Adults (PHASE2)
- A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults (PHASE1)
- Responses to Live Attenuated Influenza Virus (LAIV) in Chronic Obstructive Pulmonary Disease (COPD) (EARLY_PHASE1)
- A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza (PHASE1)
- A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People (PHASE1, PHASE2)
- Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older (PHASE3)
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Licensed Influenza Vaccine 2 CI brief — competitive landscape report
- Licensed Influenza Vaccine 2 updates RSS · CI watch RSS
- BioNTech portfolio CI
Frequently asked questions about Licensed Influenza Vaccine 2
What is Licensed Influenza Vaccine 2?
What is Licensed Influenza Vaccine 2 used for?
Who makes Licensed Influenza Vaccine 2?
What drug class is Licensed Influenza Vaccine 2 in?
What development phase is Licensed Influenza Vaccine 2 in?
What does Licensed Influenza Vaccine 2 target?
Related
- Drug class: All Vaccine drugs
- Target: All drugs targeting Not specified
- Manufacturer: BioNTech — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Influenza prevention
- Indication: Drugs for Influenza protection
- Indication: Drugs for Influenza prevention for adults and children 6 years and older
- Compare: Licensed Influenza Vaccine 2 vs similar drugs
- Pricing: Licensed Influenza Vaccine 2 cost, discount & access